Familial hypercholesterolemia: Epidemiology, Neolithic origins and modern geographic distribution

Critical Reviews in Clinical Laboratory Sciences

Volumn 48, Issue 1, 2011, Pages 1-18

  Liyanage, Khemanganee E ^a   Burnett, John R ^a,b,c   Hooper, Amanda J ^a,b,c   Van Bockxmeer, Frank M ^a,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Autosomal recessive hypercholesterolemia; familial hypercholesterolemia; familial ligand defective apolipoprotein B 100; genetic genealogy; geographical distribution; human evolutionary history; low density lipoprotein receptor; proprotein convertase subtilisin kexin type 9

Indexed keywords

APOLIPOPROTEIN B; DNA; LOW DENSITY LIPOPROTEIN;

AGRICULTURE; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GEOGRAPHIC DISTRIBUTION; HUMAN; LIPOPROTEIN METABOLISM; NEOLITHIC; PREVALENCE; PRIORITY JOURNAL; REVIEW; SCREENING;

APOLIPOPROTEINS B; FOUNDER EFFECT; GENEALOGY AND HERALDRY; GEOGRAPHY; HISTORY, ANCIENT; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MUTATION;

EID: 79958846829     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.3109/10408363.2011.565585     Document Type: Review

References (122)

1. Burnett JR, Ravine D, van Bockxmeer FM, Watts GF. Familial hypercholesterolaemia: a look back, a look ahead. Med J Aust 2005;182:552-553. (Pubitemid 40823469)
2. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler K, et al., eds. Te Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill, 2001:2863-2913.
3. Whitfeld AJ, Barrett PHR, van Bockxmeer FM, Burnett JR. Lipid disorders and mutations in the APOB gene. Clin Chem 2004;50:1725-1732. (Pubitemid 39298000)
4. Lambert G. Unravelling the functional signifcance of PCSK9. Curr Opin Lipidol 2007;18:304-309.
5. Soutar AK, Naoumova RP. Autosomal recessive hypercholesterolemia. Semin Vasc Med 2004;4:241-248. (Pubitemid 40094488)
6. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientifc Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991;303:893-896.
7. World Health Organization. Familial hypercholesterolemia. Report of a second WHO Consultation. WHO/HGN/FH/CONS/992 1999. Geneva: World Health Organization, 1999.
8. Balaresque P, Bowden GR, Adams SM, Leung HY, King TE, Rosser ZH, Goodwin J, Moisan JP, Richard C, Millward A, Demaine AG, Barbujani G, Previdere C, Wilson IJ, Tyler-Smith C, Jobling MA. A predominantly neolithic origin for European paternal lineages. PLoS Biol 2010;8:e1000285.
9. Ghirotto S, Mona S, Benazzo A, Paparazzo F, Caramelli D, Barbujani G. Inferring genealogical processes from patterns of Bronze-Age and modern DNA variation in Sardinia. Mol Biol Evol 2010;27:875-886.
10. Rees A. Familial hypercholesterolaemia: underdiagnosed and undertreated. Eur Heart J 2008;29:2583-2584.
11. Yuan G, Wang J, Hegele RA. Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. CMAJ 2006;174:1124-1129.
12. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47. (Pubitemid 16037973)
13. Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2007;4:214-225. (Pubitemid 46502094)
14. Khachadurian AK. Te inheritance of essential familial hypercholesterolemia. Am J Med 1964;37:402-407.
15. Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 1974;49:476-488.
16. de Jongh S, Lilien MR, op't Roodt J, Stroes ES, Bakker HD, Kastelein JJ. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002;40:2117-2121. (Pubitemid 36005896)
17. Wiegman A, de Groot E, Hutten BA, Rodenburg J, Gort J, Bakker HD, Sijbrands EJ, Kastelein JJ. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet 2004;363:369-370. (Pubitemid 38169546)
18. Khachadurian AK, Uthman SM. Experiences with the homozygous cases of familial hypercholesterolemia. A report of 52 patients. Nutr Metab 1973;15:132-140.
19. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004;160:407-420. (Pubitemid 39166973)
20. Kotze MJ, Langenhoven E, Warnich L, du Plessis L, Retief AE. Te molecular basis and diagnosis of familial hypercholesterolaemia in South African Afrikaners. Ann Hum Genet 1991;55:115-121.
21. Moorjani S, Roy M, Gagne C, Davignon J, Brun D, Toussaint M, Lambert M, Campeau L, Blaichman S, Lupien P. Homozygous familial hypercholesterolemia among French Canadians in Quebec Province. Arteriosclerosis 1989;9:211-216. (Pubitemid 19092104)
22. Leitersdorf E, Tobin EJ, Davignon J, Hobbs HH. Common low-density lipoprotein receptor mutations in the French Canadian population. J Clin Invest 1990;85:1014-1023. (Pubitemid 20123741)
23. Hobbs HH, Brown MS, Russell DW, Davignon J, Goldstein JL. Deletion in the gene for the low-density-lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia. N Engl J Med 1987;317:734-737 (Pubitemid 17138204)
24. Lehrman MA, Schneider WJ, Brown MS, Davis CG, Elhammer A, Russell DW, Goldstein JL. Te Lebanese allele at the low density lipoprotein receptor locus. Nonsense mutation produces truncated receptor that is retained in endoplasmic reticulum. J Biol Chem 1987;262:401-410. (Pubitemid 17000035)
25. Abifadel M, Rabes JP, Jambart S, Halaby G, Gannage-Yared MH, Sarkis A, Beaino G, Varret M, Salem N, Corbani S, Aydenian H, Junien C, Munnich A, Boileau C. Te molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifer gene. Hum Mutat 2009;30:E682-E691.
26. Dedoussis G V, Schmidt H, Genschel J. LDL-receptor mutations in Europe. Hum Mutat 2004;24:443-459. (Pubitemid 39664598)
27. Marduel M, Carrie A, Sassolas A, Devillers M, Carreau V, Di Filippo M, Erlich D, Abifadel M, Marques-Pinheiro A, Munnich A, Junien C, Boileau C, Varret M, Rabes JP, Farnier M, Luc G, Lecerf JM, Bruckert E, Bonnefont-Rousselot D, Giral P, Kalopissis A, Girardet JP, Polak M, Chanu B, Moulin P, Perrot L, Krempf M, Zair Y, Bonnet J, Ferrieres J, Ferrieres D, Bongard V, Cournot M, Reznick Y, Schlienger JL, Fredenrich A, Durlach V. Molecular spectrum of autosomal dominant hypercholesterolemia in France. Hum Mutat 2010;31:E1811-E1824.
28. Bertolini S, Cantafora A, Averna M, Cortese C, Motti C, Martini S, Pes G, Postiglione A, Stefanutti C, Blotta I, Pisciotta L, Rolleri M, Langheim S, Ghisellini M, Rabbone I, Calandra S. Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype. Arterioscler Tromb Vasc Biol 2000;20:E41-E52.
29. Liguori R, Bianco AM, Argiriou A, Pauciullo P, Giannino A, Rubba P, De Simone V. LDL receptor cDNA sequence analysis in familial hypercholesterolemia patients: 5 novel mutations with high prevalence in families originating from southern Italy. Hum Mutat 2001;17:433.
30. Romano M, Di Taranto MD, D'Agostino MN, Marotta G, Gentile M, Abate G, Mirabelli P, Di Noto R, Del Vecchio L, Rubba P, Fortunato G. Identifcation and functional characterization of LDLR mutations in familial hypercholesterolemia patients from Southern Italy. Atherosclerosis 2010;210:493-496.
31. Fouchier SW, Kastelein JJ, Defesche JC. Update of the molecular basis of familial hypercholesterolemia in Te Netherlands. Hum Mutat 2005;26:550-556. (Pubitemid 41780477)
32. Taylor A, Martin B, Wang D, Patel K, Humphries SE, Norbury G. Multiplex ligation-dependent probe amplifcation analysis to screen for deletions and duplications of the LDLR gene in patients with familial hypercholesterolaemia. Clin Genet 2009;76:69-75.
33. Taylor A, Tabrah S, Wang D, Sozen M, Duxbury N, Whittall R, Humphries SE, Norbury G. Multiplex ARMS analysis to detect 13 common mutations in familial hypercholesterolaemia. Clin Genet 2007;71:561-568. (Pubitemid 46831951)
34. Taylor A, Wang D, Patel K, Whittall R, Wood G, Farrer M, Neely RD, Fairgrieve S, Nair D, Barbir M, Jones JL, Egan S, Everdale R, Lolin Y, Hughes E, Cooper JA, Hadfeld SG, Norbury G, Humphries SE. Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clin Genet 2010;77:572-580.
35. Wright W T, Heggarty S V, Young IS, Nicholls DP, Whittall R, Humphries SE, Graham CA. Multiplex MassARRAY spectrometry (iPLEX) produces a fast and economical test for 56 familial hypercholesterolaemia-causing mutations. Clin Genet 2008;74:463-468.
36. Mozas P, Castillo S, Tejedor D, Reyes G, Alonso R, Franco M, Saenz P, Fuentes F, Almagro F, Mata P, Pocovi M. Molecular characterization of familial hypercholesterolemia in Spain: identifcation of 39 novel and 77 recurrent mutations in LDLR. Hum Mutat 2004;24:187.
37. Alonso R, Defesche JC, Tejedor D, Castillo S, Stef M, Mata N, Gomez-Enterria P, Martinez-Faedo C, Forga L, Mata P. Genetic diagnosis of familial hypercholesterolemia using a DNA-array based platform. Clin Biochem 2009;42:899-903.
38. Civeira F, Ros E, Jarauta E, Plana N, Zambon D, Puzo J, Martinez de Esteban JP, Ferrando J, Zabala S, Almagro F, Gimeno JA, Masana L, Pocovi M. Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. Am J Cardiol 2008;102:1187-1193.
39. Medeiros AM, Alves AC, Francisco V, Bourbon M. Update of the Portuguese Familial Hypercholesterolaemia Study. Atherosclerosis 2010;212:553-558.
40. Bourbon M, Duarte MA, Alves AC, Medeiros AM, Marques L, Soutar AK. Genetic diagnosis of familial hypercholesterolaemia: the importance of functional analysis of potential splice-site mutations. J Med Genet 2009;46:352-357.
41. Glynou K, Laios E, Drogari E, Tsaoussis V. Development of a universal chemiluminometric genotyping method for high-throughput detection of 7 LDLR gene mutations in Greek population. Clin Biochem 2008;41:335-342.
42. Dedoussis GV, Genschel J, Bochow B, Pitsavos C, Skoumas J, Prassa M, Lkhagvasuren S, Toutouzas P, Vogt A, Kassner U, Tomas HP, Schmidt H. Molecular characterization of familial hypercholesterolemia in German and Greek patients. Hum Mutat 2004;23:285-286.
43. Gudnason V, Sigurdsson G, Nissen H, Humphries SE. Common founder mutation in the LDL receptor gene causing familial hypercholesterolaemia in the Icelandic population. Hum Mutat 1997;10:36-44. (Pubitemid 27298947)
44. Vuorio AF, Aalto-Setala K, Koivisto UM, Turtola H, Nissen H, Kovanen PT, Miettinen TA, Gylling H, Oksanen H, Kontula K. Familial hypercholesterolaemia in Finland: common, rare and mild mutations of the LDL receptor and their clinical consequences. Finnish FH-group. Ann Med 2001;33:410-421. (Pubitemid 32881033)
45. Jensen HK. Te molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark. Dan Med Bull 2002;49:318-345. (Pubitemid 35434532)
46. Jensen HK, Jensen LG, Meinertz H, Hansen PS, Gregersen N, Faergeman O. Spectrum of LDL receptor gene mutations in Denmark: implications for molecular diagnostic strategy in heterozygous familial hypercholesterolemia. Atherosclerosis 1999;146:337-344. (Pubitemid 29418065)
47. Leren TP, Finborud TH, Manshaus TE, Ose L, Berge KE. Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. Community Genet 2008;11:26-35.
48. Leren TP, Manshaus T, Skovholt U, Skodje T, Nossen IE, Teie C, Sorensen S, Bakken KS. Application of molecular genetics for diagnosing familial hypercholesterolemia in Norway: results from a family-based screening program. Semin Vasc Med 2004;4:75-85. (Pubitemid 38393294)
49. Holla OL, Teie C, Berge KE, Leren TP. Identifcation of deletions and duplications in the low density lipoprotein receptor gene by MLPA. Clin Chim Acta 2005;356:164-171. (Pubitemid 40779898)
50. Lind S, Rystedt E, Eriksson M, Wiklund O, Angelin B, Eggertsen G. Genetic characterization of Swedish patients with familial hypercholesterolemia: a heterogeneous pattern of mutations in the LDL receptor gene. Atherosclerosis 2002;163:399-407. (Pubitemid 34615832)
51. Kuhrova V, Francova H, Zapletalova P, Freiberger T, Fajkusova L, Hrabincova E, Slovackova R, Kozak L, Slovakova R. Spectrum of low density lipoprotein receptor mutations in Czech hypercholesterolemic patients. Hum Mutat 2002;19:80.
52. Schmidt H, Kostner GM. Familial hypercholesterolemia in Austria refects the multi-ethnic origin of our country. Atherosclerosis 2000;148:431-432. (Pubitemid 30064478)
53. Goldmann R, Tichy L, Freiberger T, Zapletalova P, Letocha O, Soska V, Fajkus J, Fajkusova L. Genomic characterization of large rearrangements of the LDLR gene in Czech patients with familial hypercholesterolemia. BMC Med Genet 2010;11:115.
54. Descamps OS, Gilbeau JP, Luwaert R, Heller FR. Impact of genetic defects on coronary atherosclerosis in patients suspected of having familial hypercholesterolaemia. Eur J Clin Invest 2003;33:1-9. (Pubitemid 36051285)
55. Chmara M, Wasag B, Zuk M, Kubalska J, Wegrzyn A, Bednarska-Makaruk M, Pronicka E, Wehr H, Defesche JC, Rynkiewicz A, Limon J. Molecular characterization of Polish patients with familial hypercholesterolemia: novel and recurrent LDLR mutations. J Appl Genet 2010;51:95-106.
56. Mandelshtam M, Chakir K, Shevtsov S, Golubkov V, Skobeleva N, Lipovetsky B, Konstantinov V, Denisenko A, Gaitskhoki V, Schwartz E. Prevalence of Lithuanian mutation among St. Petersburg Jews with familial hypercholesterolemia. Hum Mutat 1998;12:255-258. (Pubitemid 28418895)
57. Zakharova FM, Damgaard D, Mandelshtam MY, Golubkov VI, Nissen PH, Nilsen GG, Stenderup A, Lipovetsky BM, Konstantinov VO, Denisenko AD, Vasilyev VB, Faergeman O. Familial hypercholesterolemia in St-Petersburg: the known and novel mutations found in the low density lipoprotein receptor gene in Russia. BMC Med Genet 2005;6:6.
58. Meshkov AN, Malyshev PP, Kukharchuk VV. [Familial hypercholesterolemia in Russia: genetic and phenotypic characteristics]. Ter Arkh 2009;81:23-28.
59. Hamilton-Craig I. Case-fnding for familial hypercholesterolemia in the Asia-Pacifc region. Semin Vasc Med 2004;4:87-92. (Pubitemid 38393295)
60. Chiou KR, Charng MJ. Detection of mutations and large rearrangements of the low-density lipoprotein receptor gene in Taiwanese patients with familial hypercholesterolemia. Am J Cardiol 2010;105:1752-1758.
61. Kondkar AA, Nair KG, Ashavaid T F. Genetic analysis of Indian subjects with clinical features of possible type IIa hypercholesterolemia. J Clin Lab Anal 2007;21:375-381. (Pubitemid 350250405)
62. Cheng X, Ding J, Zheng F, Zhou X, Xiong C. Two mutations in LDLR gene were found in two Chinese families with familial hypercholesterolemia. Mol Biol Rep 2009;36:2053-2057.
63. Punzalan FE, Sy RG, Santos RS, Cutiongco EM, Gosiengfao S, Fadriguilan E, George P, Laurie A. Low density lipoprotein-receptor (LDL-R) gene mutations among Filipinos with familial hypercholesterolemia. J Atheroscler Tromb 2005;12:276-283.
64. Ajmal M, Ahmed W, Sadeque A, Ali SH, Bokhari SH, Ahmed N, Qamar R. Identifcation of a recurrent insertion mutation in the LDLR gene in a Pakistani family with autosomal dominant hypercholesterolemia. Mol Biol Rep 2010;37:3869-3875.
65. Miyake Y, Yamamura T, Sakai N, Miyata T, Kokubo Y, Yamamoto A. Update of Japanese common LDLR gene mutations and their phenotypes: Mild type mutation L547V might predominate in the Japanese population. Atherosclerosis 2009;203:153-160.
66. Yu W, Nohara A, Higashikata T, Lu H, Inazu A, Mabuchi H. Molecular genetic analysis of familial hypercholesterolemia: spectrum and regional diference of LDL receptor gene mutations in Japanese population. Atherosclerosis 2002;165:335-342. (Pubitemid 35333360)
67. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ. Review of frst 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001;357:165-168. (Pubitemid 32108086)
68. Leren T P. Cascade genetic screening for familial hypercholesterolemia. Clin Genet 2004;66:483-487. (Pubitemid 39562009)
69. Wald DS, Bestwick JP, Wald NJ. Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis. BMJ 2007;335:599.
70. Calonge N, Guirguis-Blake J. Screening for familial hypercholesterolaemia. BMJ 2007;335:573-574. (Pubitemid 47509839)
71. Campagna F, Martino F, Bifolco M, Montali A, Martino E, Morrone F, Antonini R, Cantafora A, Verna R, Arca M. Detection of familial hypercholesterolemia in a cohort of children with hypercholesterolemia: results of a family and DNA-based screening. Atherosclerosis 2008;196:356-364.
72. Marais AD. Familial hypercholesterolaemia. Clin Biochem Rev 2004;25:49-68.
73. Leitersdorf E, Van der Westhuyzen DR, Coetzee GA, Hobbs HH. Two common low density lipoprotein receptor gene mutations cause familial hypercholesterolemia in Afrikaners. J Clin Invest 1989;84:954-961. (Pubitemid 19228369)
74. Meiner V, Landsberger D, Berkman N, Reshef A, Segal P, Seftel HC, van der Westhuyzen DR, Jeenah MS, Coetzee GA, Leitersdorf E. A common Lithuanian mutation causing familial hypercholesterolemia in Ashkenazi Jews. Am J Hum Genet 1991; 49: 443-449. (Pubitemid 21891692)
75. Garcia-Garcia AB, Real JT, Puig O, Cebolla E, Marin-Garcia P, Martinez Ferrandis JI, Garcia-Sogo M, Civera M, Ascaso JF, Carmena R, Armengod ME, Chaves FJ. Molecular genetics of familial hypercholesterolemia in Spain: Ten novel LDLR mutations and population analysis. Hum Mutat 2001;18:458-459.
76. Torrington M, Brink PA. Relevance of ancestral surname identifcation in pedigrees of Afrikaner families with familial hypercholesterolaemia. S Afr Med J 1990;77:289-292. (Pubitemid 20206624)
77. Tipping AJ, Pearson T, Morgan NV, Gibson RA, Kuyt LP, Havenga C, Gluckman E, Joenje H, de Ravel T, Jansen S, Mathew CG. Molecular and genealogical evidence for a founder efect in Fanconi anemia families of the Afrikaner population of South Africa. Proc Natl Acad Sci USA 2001;98:5734-5739. (Pubitemid 32435711)
78. Scriver CR. Human genetics: lessons from Quebec populations. Annu Rev Genomics Hum Genet 2001;2:69-101. (Pubitemid 35265001)
79. Bertolini S, Lelli N, Coviello DA, Ghisellini M, Masturzo P, Tiozzo R, Elicio N, Gaddi A, Calandra S. A large deletion in the LDL receptor gene: the cause of familial hypercholesterolemia in three Italian families: a study that dates back to the 17th century (FH-Pavia). Am J Hum Genet 1992;51:123-134
80. Te WayStation-List of LSDBs. Available at: http://www. centralmutations.org/Lsdb.php. Accessed on 31 March 2011.
81. Fokkema IF, den Dunnen JT, Taschner PE. LOVD: easy creation of a locus-specifc sequence variation database using an "LSDB-in-a-box" approach. Hum Mutat 2005;26:63-68. (Pubitemid 41040673)
82. Cotton RG, Auerbach AD, Beckmann JS, Blumenfeld OO, Brookes AJ, Brown AF, Carrera P, Cox DW, Gottlieb B, Greenblatt MS, Hilbert P, Lehvaslaiho H, Liang P, Marsh S, Nebert DW, Povey S, Rossetti S, Scriver CR, Summar M, Tolan DR, Verma IC, Vihinen M, den Dunnen JT. Recommendations for locus-specifc databases and their curation. Hum Mutat 2008;29:2-5.
83. Gen2Phen Background and Concept. Available at: http://www. gen2phen.org/about-gen2phen/background-and-concept. Accessed on 31 March 2011.
84. UCL LDLR Database. Available at: http://www.ucl.ac.uk/ldlr/LOVDv.1.1.0/. Accessed on 11 February 2011.
85. Lee SS, Mountain J, Koenig B, Altman R, Brown M, Camarillo A, Cavalli-Sforza L, Cho M, Eberhardt J, Feldman M, Ford R, Greely H, King R, Markus H, Satz D, Snipp M, Steele C, Underhill P. Te ethics of characterizing diference: guiding principles on using racial categories in human genetics. Genome Biol 2008;9:404.
86. Itan Y, Powell A, Beaumont MA, Burger J, Tomas MG. Te origins of lactase persistence in Europe. PLoS Comput Biol 2009;5:e1000491.
87. Haak W, Balanovsky O, Sanchez JJ, Koshel S, Zaporozhchenko V, Adler CJ, Der Sarkissian CS, Brandt G, Schwarz C, Nicklisch N, Dresely V, Fritsch B, Balanovska E, Villems R, Meller H, Alt KW, Cooper A. Ancient DNA from European Early Neolithic farmers reveals their Near Eastern afnities. PLoS Biol 2010;8:e1000536.
88. Bramanti B, Tomas MG, Haak W, Unterlaender M, Jores P, Tambets K, Antanaitis-Jacobs I, Haidle MN, Jankauskas R, Kind CJ, Lueth F, Terberger T, Hiller J, Matsumura S, Forster P, Burger J. Genetic discontinuity between local hunter-gatherers and central Europe's frst farmers. Science 2009;326:137-140.
89. Patin E, Barreiro LB, Sabeti PC, Austerlitz F, Luca F, Sajantila A, Behar DM, Semino O, Sakuntabhai A, Guiso N, Gicquel B, McElreavey K, Harding RM, Heyer E, Quintana-Murci L. Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes. Am J Hum Genet 2006;78:423-436. (Pubitemid 43291225)
90. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005;5:6-13. (Pubitemid 40220611)
91. Humphries SE, Drenos F, Ken-Dror G, Talmud PJ. Coronary heart disease risk prediction in the era of genome-wide association studies: current status and what the future holds. Circulation 2010;121:2235-2248.
92. Kathiresan S, Melander O, Anevski D, Guiducci C, Burtt NP, Roos C, Hirschhorn JN, Berglund G, Hedblad B, Groop L, Altshuler DM, Newton-Cheh C, Orho-Melander M. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 2008;358:1240-1249. (Pubitemid 351439225)
93. Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, Rieder MJ, Cooper GM, Roos C, Voight BF, Havulinna AS, Wahlstrand B, Hedner T, Corella D, Tai ES, Ordovas JM, Berglund G, Vartiainen E, Jousilahti P, Hedblad B, Taskinen MR, Newton-Cheh C, Salomaa V, Peltonen L, Groop L, Altshuler DM, Orho-Melander M. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008;40:189-197. (Pubitemid 351171402)
94. Park MH, Kim N, Lee JY, Park HY. Genetic loci associated with lipid concentrations and cardiovascular risk factors in a Korean population. J Med Genet 2011;48:10-5.
95. Ye SQ, Kwiterovich PO, Jr. Infuence of genetic polymorphisms on responsiveness to dietary fat and cholesterol. Am J Clin Nutr 2000;72:1275S-1284S.
96. Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, Keavney B, Collins R, Wiman B, de Faire U, Danesh J. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 2007;298:1300-1311 (Pubitemid 47443344)
97. Burman D, Mente A, Hegele RA, Islam S, Yusuf S, Anand SS. Relationship of the ApoE polymorphism to plasma lipid traits among South Asians, Chinese, and Europeans living in Canada. Atherosclerosis 2009;203:192-200.
98. Eichner JE, Dunn ST, Perveen G, Tompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 2002;155:487-495. (Pubitemid 34208040)
99. Rimbach G, Minihane AM. Nutrigenetics and personalised nutrition: how far have we progressed and are we likely to get there? Proc Nutr Soc 2009;68:162-172.
100. Weggemans RM, Zock PL, Ordovas JM, Pedro-Botet J, Katan MB. Apoprotein E genotype and the response of serum cholesterol to dietary fat, cholesterol and cafestol. Atherosclerosis 2001;154:547-555. (Pubitemid 32232151)
101. Wu K, Bowman R, Welch AA, Luben RN, Wareham N, Khaw KT, Bingham SA. Apolipoprotein E polymorphisms, dietary fat and fbre, and serum lipids: the EPIC Norfolk study. Eur Heart J 2007;28:2930-2936. (Pubitemid 350233040)
102. Fullerton SM, Clark AG, Weiss KM, Nickerson DA, Taylor SL, Stengard JH, Salomaa V, Vartiainen E, Perola M, Boerwinkle E, Sing CF. Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism. Am J Hum Genet 2000;67:881-900.
103. van Bockxmeer FM. ApoE and ACE genes: impact on human longevity. Nat Genet 1994;6:4-5. (Pubitemid 24191902)
104. Becher JC, Keeling JW, McIntosh N, Wyatt B, Bell J. Te distribution of apolipoprotein E alleles in Scottish perinatal deaths. J Med Genet 2006;43:414-418.
105. Corbo RM, Ulizzi L, Scacchi R, Martinez-Labarga C, De Stefano GF. Apolipoprotein E polymorphism and fertility: a study in pre-industrial populations. Mol Hum Reprod 2004;10:617-620. (Pubitemid 39136822)
106. Edison RJ, Berg K, Remaley A, Kelley R, Rotimi C, Stevenson RE, Muenke M. Adverse birth outcome among mothers with low serum cholesterol. Pediatrics 2007;120:723-733. (Pubitemid 47549559)
107. Infante-Rivard C, Levy E, Rivard GE, Guiguet M, Feoli-Fonseca JC. Small babies receive the cardiovascular protective apolipoprotein epsilon 2 allele less frequently than expected. J Med Genet 2003;40:626-629. (Pubitemid 37046919)
108. Ozornek H, Ergin E, Jeyendran RS, Ozay AT, Pillai D, Coulam C. Is apolipoprotien E codon 112 polymorphisms associated with recurrent pregnancy loss? Am J Reprod Immunol 2010;64:87-92.
109. Fagundes NJ, Ray N, Beaumont M, Neuenschwander S, Salzano FM, Bonatto SL, Excofer L. Statistical evaluation of alternative models of human evolution. Proc Natl Acad Sci USA 2007;104:17614-17619. (Pubitemid 350210884)
110. Zeegers MP, van Poppel F, Vlietinck R, Spruijt L, Ostrer H. Founder mutations among the Dutch. Eur J Hum Genet 2004;12:591-600. (Pubitemid 39077169)
111. Shen H, Damcott CM, Rampersaud E, Pollin TI, Horenstein RB, McArdle PF, Peyser PA, Bielak LF, Post WS, Chang YP, Ryan KA, Miller M, Rumberger JA, Sheedy PF, 2nd, Shelton J, O'Connell JR, Shuldiner AR, Mitchell BD. Familial defective apolipoprotein B-100 and increased low-density lipoprotein cholesterol and coronary artery calcifcation in the old order amish. Arch Intern Med 2010;170:1850-1855.
112. Soria LF, Ludwig EH, Clarke HR, Vega GL, Grundy SM, McCarthy BJ. Association between a specifc apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci USA 1989;86:587-591. (Pubitemid 19037786)
113. Myant NB, Forbes SA, Day IN, Gallagher J. Estimation of the age of the ancestral arginine3500-glutamine mutation in human apoB-100. Genomics 1997;45:78-87. (Pubitemid 27449386)
114. Miserez AR, Muller PY. Familial defective apolipoprotein B-100: a mutation emerged in the mesolithic ancestors of Celtic peoples? Atherosclerosis 2000;148:433-436. (Pubitemid 30064479)
115. Cavalli-Sforza LL, Bodmer WF. Te Genetics of Human Populations. San Francisco: Freeman, 1971:483-488.
116. Eroglu Z, Selvi N, Kosova B, Biray C, Kumral E, Topcuoglu N, Kayikcioglu M. Absence of apolipoprotein B-3500 mutation in Turkish patients with coronary and cerebrovascular atherosclerosis. Anadolu Kardiyol Derg 2008;8:7-9. (Pubitemid 351266059)
117. Castillo S, Tejedor D, Mozas P, Reyes G, Civeira F, Alonso R, Ros E, Pocovi M, Mata P. Te apolipoprotein B R3500Q gene mutation in Spanish subjects with a clinical diagnosis of familial hypercholesterolemia. Atherosclerosis 2002;165:127-135. (Pubitemid 35223174)
118. Bednarska-Makaruk M, Bisko M, Pulawska MF, Hofman-Zacharska D, Rodo M, Roszczynko M, Solik-Tomassi A, Broda G, Polakowska M, Pytlak A, Wehr H. Familial defective apolipoprotein B-100 in a group of hypercholesterolaemic patients in Poland. Identifcation of a new mutation Tr3492Ile in the apolipoprotein B gene. Eur J Hum Genet 2001;9:836-842. (Pubitemid 34030714)
119. Gasparovic J, Basistova Z, Fabryova L, Wsolova L, Vohnout B, Raslova K. Familial defective apolipoprotein B-100 in Slovakia: are diferences in prevalence of familial defective apolipoprotein B-100 explained by ethnicity? Atherosclerosis 2007;194:e95-107.
120. Milman N, Pedersen P. Evidence that the Cys282Tyr mutation of the HFE gene originated from a population in southern Scandinavia and spread with the Vikings. Clin Genet 2003;64:36-47. (Pubitemid 36949947)
121. Distante S, Robson KJ, Graham-Campbell J, Arnaiz-Villena A, Brissot P, Worwood M. Te origin and spread of the HFE-C282Y haemochromatosis mutation. Hum Genet 2004;115:269-279. (Pubitemid 39247867)
122. Hardelid P, Cortina-Borja M, Munro A, Jones H, Cleary M, Champion MP, Foo Y, Scriver CR, Dezateux C. Te birth prevalence of PKU in populations of European, south Asian and sub-Saharan African ancestry living in south east England. Ann Hum Genet 2008;72:65-71.